3V35

Aldose reductase complexed with a nitro compound

Summary for 3V35

• Entry DOI: 10.2210/pdb3v35/pdb
• Related: 3V36
• Descriptor: Aldose reductase, NADP NICOTINAMIDE-ADENINE-DINUCLEOTIDE PHOSPHATE, 2-[(5-nitro-1,3-thiazol-2-yl)carbamoyl]phenyl acetate, ... (5 entities in total)
• Functional Keywords: aldose reductase, oxidoreductase
• Biological source: Homo sapiens (human)
• Cellular location: Cytoplasm: P15121
• Total number of polymer chains: 1
• Total formula weight: 40801.54

Authors

Zheng, X.,Zhang, L.,Chen, Y.,Luo, H.,Hu, X. (deposition date: 2011-12-13, release date: 2012-08-29, Last modification date: 2023-11-08)

Primary citation

Zheng, X.,Zhang, L.,Chen, W.,Chen, Y.,Xie, W.,Hu, X.
Partial inhibition of aldose reductase by nitazoxanide and its molecular basis.
Chemmedchem, 7:1921-1923, 2012

PubMed Abstract: A little is more than enough: Aldose reductase (AR) is a potential target in a wide range of diseases but its utility may be limited by the side effects caused by complete inhibition. Furthermore, known inhibitors of AR have suffered in clinical evaluation due to poor bioavailability. Here, the clinically used antiprotozoal drug nitazoxanide with proven bioavailability has been shown to partially inhibit AR, potentially circumventing the negatives effects of complete enzyme inhibition.

PubMed: 22890894
DOI: 10.1002/cmdc.201200333

Experimental method

X-RAY DIFFRACTION (1.9 Å)